MED-EL

What MED-EL does

MED-EL Elektromedizinische Geräte GmbH is an Austrian, privately held hearing implant company headquartered in Innsbruck, founded in 1990 by Ingeborg and Erwin Hochmair on the basis of their pioneering 1977 research into the world's first micro-electronic multi-channel cochlear implant. The company designs, manufactures, and sells a portfolio of implantable hearing solutions spanning cochlear implants (SYNCHRONY 2, SONNET 3, RONDO 3), Electric Acoustic Stimulation (SYNCHRONY 2 for EAS, SONNET 3 EAS), middle ear implants (VIBRANT SOUNDBRIDGE with SAMBA 2), bone conduction implants (BONEBRIDGE, plus ADHEAR non-surgical bone conduction), and accessories such as AudioStream and the SONNET 3 rechargeable battery family. Core technical differentiators include the SYNCHRONY self-aligning magnet enabling MRI at up to 3.0 Tesla without magnet removal, a lifetime worldwide MRI guarantee covering all MED-EL multichannel cochlear implants since 1994, and ISO/IEC 27001:2022 certification for the Remote Care cloud platform. Distribution is hybrid — direct enterprise field sales to hospitals and ENT/audiology clinics, a certified distributor network, 30 country offices, and the myMED-EL accessories storefront in the UK and U.S. — reaching 136 countries through approximately 2,700 employees from around 80 nations.

The company serves two primary customer segments: individuals with hearing loss ranging from infants (FDA approval as young as 7 months) to seniors, and the hearing healthcare professionals (ENT surgeons, audiologists, neurotologists) who assess, implant, and program the devices. Revenue is generated primarily through one-time hardware sales of implant systems and audio processors to hospitals and clinics, with a recurring aftermarket layer from processor upgrades (e.g., the SONNET 3 Standard Pro / Micro Pro batteries launched in March 2026) and accessories sold via myMED-EL Shop. Pricing is opaque and negotiated through insurance reimbursement, government healthcare programs, and direct hospital procurement, with no public list prices. The customer journey is supported by an ecosystem of professional education (MED-EL Academy, Surgical Video Library), remote clinical services (Remote Check, Remote Care), rehabilitation apps (ReDi, AudioKey 3, HearCare MED-EL), and a peer community (Hearpeers), with bimodal streaming interoperability enabled through the Starkey DualSync partnership.

Name

MED-EL

Legal name

MED-EL Elektromedizinische Geräte GmbH

Website

https://medel.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

MED-EL is a privately held Austrian hearing implant company that designs and sells cochlear, bone conduction, middle ear, and EAS implant systems across 136 countries. It serves individuals with hearing loss and the ENT surgeons and audiologists who implant and program its devices.

Ownership category

akta.pro rank

Product category

Hearing Implants

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Otology & Neurotology (Ear/Hearing/Balance) (HLAKAMAC)

Keywords

• Cochlear implant systems
• Bone conduction implants
• Middle ear implants
• Hearing implant solutions
• Audio processors

Headquarters

HQ city

Innsbruck

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Hearing Implant Hardware Sales: MED-EL generates revenue primarily from the sale of implantable hearing devices (cochlear implants, bone conduction implants, middle ear implants) and external audio processors (SONNET 3, RONDO 3, SONNET 2). Revenue is generated through一次性 (one-time) device sales to hospitals/clinics and replacement/upgrade cycles for audio processors. The company sells via direct sales teams and a global network of distributors and clinic partners across 136 countries.
2. Audio Processor Accessories and Upgrades: MED-EL sells accessories including rechargeable battery packs (Standard Pro, Micro Pro), connectivity devices (AudioStream), and replacement parts through its myMED-EL e-commerce shop, generating recurring revenue from existing implant recipients.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels9 records

Core offering

MED-EL manufactures and sells implantable hearing devices, including cochlear implants (SYNCHRONY 2), Electric Acoustic Stimulation systems (SONNET 3 EAS), bone conduction implants (BONEBRIDGE), middle ear implants (VIBRANT SOUNDBRIDGE), and auditory brainstem implants, along with external audio processors (SONNET 3, RONDO 3, SAMBA 2) and accessories. Devices are sold to hospitals, ENT clinics, and audiology professionals across 136 countries for implantation in patients with all types of hearing loss. The company also operates a remote care platform, mobile applications for device management and rehabilitation, and the myMED-EL e-commerce portal for accessories.

Product overview

MED-EL offers a comprehensive portfolio of hearing implant solutions including cochlear implants (SYNCHRONY 2, RONDO 3, SONNET 3), Electric Acoustic Stimulation systems (SONNET 3 EAS), middle ear implants (VIBRANT SOUNDBRIDGE with SAMBA 2), bone conduction implants (BONEBRIDGE), and non-implant bone conduction systems (ADHEAR). The portfolio also includes audio processors, accessories (AudioStream, WaterWear), mobile applications (HearCare MED-EL, AudioKey 3, ReDi App), online platforms (myMED-EL, Hearpeers community), and professional training tools (MED-EL Academy, ReDi Studio). The company provides solutions across all types of hearing loss and serves patients in 136 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Hearpeers: MED-EL's international community for hearing implant recipients and candidates, offering peer support and connection.
• STIWELL
• AUDIOVERSUM
• myMED-EL

Products and services

• SYNCHRONY 2

Quantifiable outcome

• FDA approval for cochlear implants for children as young as 7 months old — the first and only FDA-approved option for infants of that age (December 2024)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature5 records

Partnerships

Five partnerships are on record, tiered minor, core and moderate.

• CanonminorGTM or Marketing Partner · 1 October 2025Canon and MED-EL partnered to provide 13 children in Nigeria with cochlear implants and a photography training workshop. The program aimed to enhance creativity, confidence, and communication skills among children with hearing impairments. This represents a corporate social responsibility initiative rather than a commercial partnership.
• BHM-TechcoreStrategic or Co-development Partner · 1 July 2024MED-EL acquired Austrian bone conduction hearing systems company BHM-Tech in July 2024 (deal publicly disclosed September 12, 2024). The acquisition aims to expand MED-EL's product portfolio in bone conduction technologies, incorporating BHM-Tech's advanced bone conduction technology into MED-EL's hearing solutions offering. BHM-Tech specializes in bone conduction hearing systems, complementing MED-EL's existing BONEBRIDGE bone conduction implant and ADHEAR non-surgical bone conduction system.
• StarkeycoreTechnology or IntegrationMED-EL and Starkey partnered to create DualSync Technology — a bimodal streaming partnership enabling seamless audio streaming from iOS devices simultaneously to MED-EL cochlear implants and certain Starkey hearing aids. This integration allows users who wear a cochlear implant on one ear and a hearing aid on the other to receive unified wireless audio streaming, addressing bimodal hearing users.
• European Hearing Instrument Manufacturers Association (EHIMA)moderateStrategic or Co-development PartnerMED-EL is a member of EHIMA, collaborating with leading companies in the hearing industry to exchange insights and drive industry-wide improvements. The EHIMA Cybersecurity Working Group has published a whitepaper outlining best practices for the secure fitting of hearing devices. This membership supports MED-EL's engagement in industry standards and cybersecurity best practices.
• Health-ISAC (Health Information Sharing and Analysis Center)moderateStrategic or Co-development PartnerMED-EL participates in Health-ISAC, a global non-profit member-driven organization fostering collaboration among healthcare stakeholders including medical device manufacturers and clinics to share threat intelligence and strengthen collective defenses against cybersecurity threats.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Widex: Widex is a Danish hearing-aid manufacturer, now part of WS Audiology (with Sivantos). It is not a direct cochlear implant competitor but competes for the same audiologist relationships and is adjacent to MED-EL's bimodal-hearing patient population.
• GN Hearing (GN Store Nord): GN Hearing is a major hearing-aid manufacturer (ReSound, Beltone, Jabra) and, through its AudioNova network, competes for the same audiology professional relationships that drive MED-EL's cochlear implant referrals. It represents a broader hearing-healthcare incumbent rather than a direct cochlear implant competitor.
• Demant A/S: Demant is a Danish-listed hearing healthcare group owning Oticon, Bernafon, Sonic, and Oticon Medical. While primarily a hearing-aid leader, its Oticon Medical division competes with MED-EL in bone-anchored and cochlear implants, sharing the same audiologist and ENT professional channel.
• Sonova Holding AG: Sonova is a Swiss-listed hearing healthcare conglomerate owning Advanced Bionics (cochlear implants) and Phonak (hearing aids). It competes with MED-EL in cochlear implants via Advanced Bionics and overlaps in professional audiology channels globally, but operates at much larger scale across a broader hearing-aid portfolio.
• Starkey Hearing Technologies: Starkey is a US-based private hearing-aid leader partnered with MED-EL via DualSync Technology for bimodal streaming. While primarily a hearing-aid company, Starkey overlaps with MED-EL in audiologist channels and serves the same bimodal-hearing patients on the hearing-aid side.

Direct peers

• Cochlear Limited: Cochlear Limited is the global market leader in cochlear implants, headquartered in Australia and publicly listed on the ASX. It directly competes with MED-EL across cochlear implant systems, sound processors, and bone conduction solutions, with comparable product categories (Nucleus, Kanso, Osia) and overlapping distribution through ENT clinics and hospitals worldwide.
• Oticon Medical: Oticon Medical, part of the Danish Demant Group, manufactures bone-anchored hearing systems (Ponto) and was historically a cochlear implant competitor. It competes with MED-EL's BONEBRIDGE and BHM-Tech bone conduction portfolio in the conductive/mixed hearing loss and single-sided deafness segments.
• Advanced Bionics (Sonova): Advanced Bionics is a US-based cochlear implant manufacturer wholly owned by Sonova. It directly competes with MED-EL's cochlear implant portfolio (Naida CI, Marvel CI sound processors) and serves the same ENT surgeon and hospital channels, making it one of MED-EL's closest head-to-head competitors in the U.S. and Europe.

Emerging players

• Envoy Medical Corporation: Envoy Medical is a US-listed emerging player developing fully implanted hearing devices, including the Esteem middle ear implant and the Acclaim cochlear implant. It overlaps with MED-EL's VIBRANT SOUNDBRIDGE middle ear implant and SYNCHRONY cochlear implant, though at a much earlier commercialisation stage.
• Nurotron Biotechnology: Nurotron is a China-based cochlear implant manufacturer with regulatory approvals in China and select emerging markets. It competes at the value end of the cochlear implant market and is an emerging alternative to MED-EL in price-sensitive geographies, particularly in Asia.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/MEDELnetwork
• Facebookfacebook.com/medel.hearlife
• LinkedInlinkedin.com/company/med-el
• Instagraminstagram.com/medel_global
• Xx.com/medel

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MED-EL